benefits of microdosing glp-1 Let's talk about “microdosing” GLP-1s — because this trend needs to stop. This idea didn't come from science. It came from inexperienced prescribers who saw patients experiencing side effects at therapeutic doses — Found Health Launches GLP-1 Microdosing

Several methods are introduced to increase the half-life of GLP-1 including: (i) modifying peptides to make them resistant to cleavage by DPP-4, such as exenatide twice daily and lixisenatide, (ii) attaching free fatty acid side chains to liraglutide and semaglutide, which enhances their binding to plasma albumin thereby preventing renal filtration of GLP-1 and prolonging their action in vivo [36, 37], (iii) conjugation of albumin or the Fc fragment of IgG to GLP-1 molecule is used in albiglutide and dulaglutide [37, 38], (iv) development of modified nanoparticles for the controlled release of exenatide-LAR (long-acting release) that provide prolonged release of the peptide [39], and finally, (v) chemical permeation enhancers such as sodium salcaprozate (SNAC) could be utilized to overcome the low permeability and high enzymatic degradation of the gastrointestinal tract of GLP-1 analog that is administrated orally such as semaglutide [40]

Comparison of group medical visits combined with intensive weight management vs group medical visits alone for glycemia in patients with type 2 diabetes: a noninferiority randomized clinical trial

GLP-1s reduce caloric intake in terms of proteins, fats, and carbs, which are necessary to make glucose, the bodys primary source of energy

These benefits were subsequently confirmed in well-powered studies specifically designed to evaluate kidney outcomes [1, 2]

These medications are recognized as powerful tools, offering unprecedented potential for weight loss and metabolic improvements